Multiple Ascending Dose Study of Oxfendazole in Healthy Adult Volunteers

Inclusion Criteria

• Males and nonpregnant females between the ages of 18 and 45 years, inclusive.
• Women of childbearing potential* must agree to practice adequate contraception** for the 28-day period before Day 0 through 4 months after the last dose of study medication.
• A woman is considered of childbearing potential unless surgically sterile (tubal ligation, bilateral oophorectomy, or hysterectomy) or post-menopausal (=1 year).

**Acceptable birth control methods include but are not limited to: abstinence from sexual intercourse with men; monogamous relationship with a vasectomized partner; double-barrier methods (condoms, diaphragms, spermicides); intrauterine devices; and licensed hormonal methods.

• In good health, as judged by the investigator and determined by vital signs*

*Temperature 50 bpm, systolic blood pressure 89 mmHg, diastolic blood pressure = 18 and = 45 may be enrolled at the discretion of the principal investigator or designated licensed clinical investigator. Acceptable screening laboratories: Hemoglobin, white blood cell (WBC) count, neutrophil, and platelet counts, INR and PTT within normal ranges. AST =100.4°F (>=38.0°C) or acute illness within 3 days before administration of study drug (subject may be rescheduled).

• Chronic or acute medical disorder*
• Disorders of the cardiac, pulmonary, liver, kidney, neurologic, gastrointestinal or other system, such that in the opinion of the investigator participation in the study creates additional risk to the subject, or to the validity of the study.
• Use of chronic systemic medications* *Intermittent use of over the counter medications such as acetaminophen, ibuprofen, cold and sinus medications are permitted for enrollment Topical medications, nasal steroids are permitted throughout the study. Use of prescription medications used less than once per week on average are permitted for enrollment. If the subject has taken a short term prescription medication within the past 30 days (e.g. an antibiotic), they should be postponed from enrollment until 30 days have elapsed since the last dose.
• Has history of sensitivity to related benzimidazole compounds (e.g., albendazole, mebendazole).
• A diagnosis of schizophrenia, bipolar disease, or history of hospitalization for a psychiatric condition or previous suicide attempt.
• A history of treatment for any other psychiatric disorder in the past 3 years.*

*Past treatment for ADHD does not exclude participants from enrollment as long as the medications have been discontinued for a minimum of 3 months and symptoms are well controlled.

• Received an experimental agent* within 1 month before administration of study drug or expect to receive an experimental agent during the 10 or 14-day study period.

*Vaccine, drug, biologic, device, blood product, or medication.

• Any condition that would, in the opinion of the investigator, interfere with the study.*

*This includes any condition that would place them at an unacceptable risk of injury, render them unable to meet the requirements of the protocol, or that may interfere with successful completion of the study.

• A history of heavy alcohol* or illicit drug use**, or history of substance abuse#.

*On average, greater than 7 alcoholic drinks per week. .

**Other than occasional marijuana use (less than once per week for the past 60 days is acceptable).

#Alcohol or illicit drugs within the past 3 years.

• History of chronic tobacco use in the past 60 days.* *A history of occasional tobacco use (less than 1 pack per week on average) is acceptable. Individuals will be counseled to abstain from use of tobacco and marijuana from screening through day 10 or 14.